Deinove appoints business development director

Michael Krel will form industrial alliances with leading chemicals companies

Deinove, a French specialist in Deinococcus bacteria for biofuels, green chemistry and antibiotics, has appointed Michael Krel to the newly created post of executive vice president, business development.

Krel was previously business development manager at Metabolic Explorer, a green chemistry company specialising in the development of fermentation processes for commodity chemicals.

Deinove chief executive Jacques Biton said Krel’s main role will be to form collaborations and licensing deals with biofuels and chemicals companies worldwide.

You may also like

Manufacturing

UK pharmaceutical manufacturers struggling to meet F-Gas compliance amid ageing cooling infrastructure

A new Aggreko report reveals that nearly all UK pharmaceutical manufacturers are facing barriers to upgrading cooling systems ahead of the accelerating F-Gas phase-down timeline
Manufacturing

Labtex - Fresh thinking and innovative solutions

Labtex states: "We are proud to provide unique solutions for laboratories and pilot plants across the UK"
Manufacturing

Nemera partners with Therakind to expand nasal drug delivery portfolio with DriDose dry powder platform

The manufacturer has announced a strategic partnership with UK pharmaceutical company Therakind to advance the DriDose intranasal dry powder platform, adding dry powder delivery capabilities to complement Nemera's existing liquid nasal formulation offering
Manufacturing

L.B. Bohle hosts successful continuous manufacturing workshop in Brazil

Focus on continuous wet granulation and drying for research, development and small-scale production
Manufacturing

Swiss Rockets collaborates with Lonza to advance Torqur’s oncology drug candidate bimiralisib into late-stage clinical development

Lonza to provide cGMP manufacturing and technical support to advance bimiralisib into late-stage clinical development
Manufacturing

Symbiosis completes full ICH climatic zone coverage with new stability chamber addition

Sterile injectable CDMO Symbiosis Pharmaceutical Services has installed a 30°C stability chamber at its Stirling facility, completing its coverage of all four ICH-defined climatic zones and strengthening its commercial drug product supply capabilities for global markets
Regulatory

FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions

Eli Lilly has received FDA approval for Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight that requires no fasting or water restrictions, with clinical trial participants on the highest dose losing an average of 27 pounds
Subscribe now